Search our Database of Scientific Publications and Authors

I’m looking for a

    4465 results match your criteria American journal of clinical oncology[Journal]

    1 OF 90

    Induction Therapies Plus Surgery Versus Exclusive Radiochemotherapy in Stage IIIA/N2 Non-Small Cell Lung Cancer (NSCLC).
    Am J Clin Oncol 2017 Nov 7. Epub 2017 Nov 7.
    BioIRC, Centre for Biomedical Research, Kragujevac, Serbia.
    In spite of the growing body of data from prospective randomized clinical trials (PRCTs) and meta-analyses, the optimal treatment approach in patients with stage IIIA non-small cell lung cancer remains unknown. This review focuses on the available data directly confronting induction chemotherapy or induction radiochemotherapy (RT-CHT) when followed by surgery with exclusive RT-CHT. Seven PRCTs and 4 meta-analyses investigated this issue. Read More

    Travel Distance as a Barrier to Receipt of Adjuvant Radiation Therapy After Radical Prostatectomy.
    Am J Clin Oncol 2017 Oct 17. Epub 2017 Oct 17.
    *Harvard Medical School †Harvard Radiation Oncology Program ‡Department of Radiation Oncology, Brigham and Women's Hospital/Dana-Farber Cancer Institute, Boston, MA.
    Objectives: Following radical prostatectomy (RP), adjuvant radiation therapy (RT) decreases biochemical recurrence and potentially improves metastasis-free and overall survival for patients with high-risk pathologic features. Since adjuvant RT typically occurs daily over several weeks, the logistical challenges of extensive traveling may be a significant barrier to its use. We examined the association between distance to treatment facility and use of adjuvant RT. Read More

    Dose Escalation Study of Concurrent Chemoradiotherapy With the Use of Involved-field Conformal Radiotherapy and Accelerated Hyperfractionation in Combination With Cisplatin and Vinorelbine Chemotherapy for Stage III Non-small Cell Lung Cancer: The Final Report.
    Am J Clin Oncol 2017 Oct 17. Epub 2017 Oct 17.
    Departments of *Clinical Oncology †Radiology §Respiratory Medicine ∥Premier Preventive Medicine, Graduate School of Medicine, Osaka City University ¶Department of Thoracic Malignancy, Osaka Prefectural Medical Center for Respiratory and Allergic Diseases, Osaka ‡Department of Radiology, Izumi Municipal Hospital, Izumi, Japan.
    Objectives: A phase I study to determine a recommended dose of thoracic radiotherapy using accelerated hyperfractionation for unresectable non-small cell lung cancer was conducted.

    Materials And Methods: We used chemotherapy of a cisplatin doublet and 2 dose levels of radiation with accelerated hyperfractionation. The radiation dose levels were: a total dose of 60 Gy in 40 fractions at level 1, and 66 Gy in 44 fractions at level 2. Read More

    Patterns of Failure in Patients With Adult Medulloblastoma Presenting Without Extraneural Metastasis.
    Am J Clin Oncol 2017 Oct 17. Epub 2017 Oct 17.
    *Department of Radiation Oncology, University of Florida College of Medicine, Gainesville †Department of Radiation Oncology, University of Florida College of Medicine, Jacksonville, FL.
    Objectives: The objective of this study is to evaluate long-term outcomes, specifically patterns of tumor recurrence, in patients with adult medulloblastoma treated with radiotherapy.

    Methods: We recorded outcomes of 28 (median age, 25 y) patients 18 years old or above with M0 to M3 medulloblastoma treated between 1971 and 2012. Among them, 61% had standard-risk disease. Read More

    Diagnosis of Axillary Web Syndrome in Patients After Breast Cancer Surgery: Epidemiology, Risk Factors, and Clinical Aspects: A Prospective Study.
    Am J Clin Oncol 2017 Oct 17. Epub 2017 Oct 17.
    Breast Diseases Division of Universidade Federal de São Paulo, Sao Paulo, Brazil.
    Objectives: Axillary web syndrome (AWS) is a complication after breast cancer surgery associated with the axillary approach. We defined a diagnosis tool as well as evaluated cord frequency, characteristics, and risk factors.

    Methods: A prospective cohort study of 173 women followed-up at Breast Diseases Division of Universidade Federal de São Paulo between July 2014 and September 2015 was established as an evaluation protocol to diagnose AWS. Read More

    "Lost to Follow-up" Among Adult Cancer Survivors.
    Am J Clin Oncol 2017 Oct 12. Epub 2017 Oct 12.
    *James Graham Brown Cancer Center, University of Louisville, Louisville, KY †Division of Hematology and Oncology, Roswell Park Cancer Institute, Buffalo, NY ‡Department of Medicine ∥Division of Hematology/Oncology, Sinai Hospital, Baltimore, MD §Apex Epidemiology Baltimore, MD.
    Background: Follow-up cancer care is important for patients who have received IV chemotherapy but some patients discontinue their care and are lost to follow-up (LFU) at the cancer center where they were treated. The purpose of this study was to determine what proportion of cancer survivors are LFU at 5 years after treatment, the timing of LFU, and the characteristics of those who do not continue survivorship care.

    Methods: Adult patients with cancer who were treated with chemotherapy at a large community teaching hospital in 2006 and 2007 were identified and linked with State tumor registry data. Read More

    Clinical Characteristics of Patients Experiencing Pathologic Complete Response Following Neoadjuvant Therapy for Borderline Resectable/Locally Advanced Pancreatic Adenocarcinoma.
    Am J Clin Oncol 2017 Sep 29. Epub 2017 Sep 29.
    Departments of *Medicine †Surgery, Indiana University School of Medicine, Indianapolis, IN.
    Objectives: The purpose of this study is to describe clinical characteristics and outcomes of patients with borderline resectable pancreatic cancer (BRPC) or locally advanced pancreatic cancer (LAPC) who achieved pathologic complete response (pCR) following neoadjuvant therapy.

    Materials And Methods: A single institution clinical database for patients with pancreatic ductal adenocarcinoma was queried. Between 2008 and 2014 patients were identified with BRPC and LAPC, who underwent surgical resection after receiving neoadjuvant treatment. Read More

    A Phase1b Dose Escalation Study of Recombinant Circularly Permuted TRAIL in Patients With Relapsed or Refractory Multiple Myeloma.
    Am J Clin Oncol 2017 Sep 19. Epub 2017 Sep 19.
    *Department of Hematology, Chang Zheng Hospital, Second Military Medical University, Shanghai †Department of Lymphoma Center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Tianjin ‡Department of Hematology, Second Hospital of Hebei Medical University, Shijiazhuang, Hebei §Departmentof Hematology, Peking University Third Hospital ∥Department of Hematology, Beijing Friendship Hospital #Department of Hematology, Beijing Chao-Yang Hospital, Capital Medical University **Beijing Sunbio Biotech Co. Ltd ¶Department of Hematology, Jinan Military General Hospital, Jinan, Shandong, China.
    Objectives: Circularly permuted tumor necrosis factor-related apoptosis-inducing ligand (CPT), or CPT, is a novel antitumor drug candidate. This phase 1b study evaluated the safety, tolerability, pharmacokinetics (PK), and efficacy of single-agent CPT in patients with relapsed or refractory multiple myeloma (RRMM), and aimed to identify the recommended dose for the phase 2 study.

    Materials And Methods: Patients received single or multiple doses (once daily for 5 consecutive days per 21-d cycle) of CPT intravenous infusion at doses of 5, 6. Read More

    Phase I/II Study of S-1 Plus Cisplatin Alternating With S-1 Plus Docetaxel in Patients With Advanced Gastric Cancer.
    Am J Clin Oncol 2017 Sep 19. Epub 2017 Sep 19.
    *Department of Gastroenterology and Hematology, Faculty of Medicine, University of Toyama †Department of Surgery, Takaoka City Hospital, Takaoka ∥Division of Biostatistics and Clinical Epidemiology, University of Toyama, Toyama ‡Department of Gastroenterology, Tachikawa General Hospital, Nagaoka, Niigata §Department of Oncology, Mitsubishi Kyoto Hospital, Kyoto, Japan.
    Objectives: To investigate the usefulness of S-1 plus cisplatin alternating with S-1 plus docetaxel as first-line treatment in patients with advanced gastric cancer, we conducted a phase I/II study to determine the maximum tolerated dose and recommended dose, and evaluate efficacy and toxicity.

    Materials And Methods: Patients with histologically confirmed unresectable and recurrent gastric cancer were enrolled in this study. Cisplatin was administered on day 1 and the dose escalated by 10 mg/m from a starting dose of 40 mg/m in the phase I part. Read More

    Radiation and Immunotherapy in High-grade Gliomas: Where Do We Stand?
    Am J Clin Oncol 2017 Sep 12. Epub 2017 Sep 12.
    Departments of *Stitch Radiation Oncology †Neurosurgery, Brain and Spine Center, Weill Cornell Medical College/NewYork-Presbyterian Hospital, New York, NY.
    High-grade glioma is the most common primary brain tumor, with glioblastoma multiforme (GBM) accounting for 52% of all brain tumors. The current standard of care (SOC) of GBM involves surgery followed by adjuvant fractionated radiotherapy and chemotherapy. However, little progress has been made in extending overall survival, progression-free survival, and quality of life. Read More

    The Evolving Role of Tumor Treating Fields in Managing Glioblastoma: Guide for Oncologists.
    Am J Clin Oncol 2017 Aug 24. Epub 2017 Aug 24.
    *Levine Cancer Institute †Southeast Radiation Oncology Group, Charlotte, NC ‡Brain & Spine Tumor Center, Northwestern Medicine Cancer Center Warrenville §Northwestern Medicine Chicago Proton Center, Chicago, IL ∥Department of Radiation Oncology, Mayo Clinic, Rochester, MN ¶Department of Radiation Oncology, Miami Cancer Institute, Miami, FL.
    Glioblastoma (GBM) is a devastating brain tumor with poor prognosis despite advances in surgery, radiation, and chemotherapy. Survival of patients with glioblastoma remains poor, with only 1 in 4 patients alive at 2 years, and a 5-year survival rate of about 5%. Recurrence is nearly universal and, after recurrence, prognosis is poor with very short progression-free survival and overall survival (OS). Read More

    Hypoalbuminemia is a Predictive Factor for Fistula Formation in Recurrent Cervical Cancer.
    Am J Clin Oncol 2017 Aug 16. Epub 2017 Aug 16.
    *Division of Gynecologic Oncology †Department of Obstetrics and Gynecology, The University of Texas Southwestern Medical Center, Dallas, TX.
    Objective: Antivascular endothelial growth factor monoclonal antibodies inhibit tumor angiogenesis, consequently impeding the recruitment of new vasculature to existing and new tumor lesions. We sought to evaluate toxicities in women with recurrent cervical cancer after receiving bevacizumab combination chemotherapy.

    Methods: A review was conducted of women with recurrent and metastatic cervical cancer who were treated with salvage chemotherapy with or without bevacizumab between 2005 and 2015. Read More

    Six-Year Results From a Phase I/II Trial for Hypofractionated Accelerated Partial Breast Irradiation Using a 2-Day Dose Schedule.
    Am J Clin Oncol 2017 Aug 4. Epub 2017 Aug 4.
    *Provision Proton Therapy Center, Knoxville, TN †Oakland University William Beaumont School of Medicine, Royal Oak §Michigan Healthcare Professionals, 21st Century Oncology, Farmington Hills, MI ‡Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH.
    Background: To report 6-year outcomes from a phase I/II trial using balloon-based brachytherapy to deliver APBI in 2 days.

    Methods: A total of 45 patients with early-stage breast cancer received adjuvant APBI in 2 days with high-dose rate (HDR) brachytherapy totaling 2800 cGy in 4 fractions (700 cGy BID) using a balloon-based applicator as part of a prospective phase I/II clinical trial. All patients had negative margins and skin spacing ≥8 mm. Read More

    A Phase I Clinical Trial of the Phosphatidylserine-targeting Antibody Bavituximab in Combination With Radiation Therapy and Capecitabine in the Preoperative Treatment of Rectal Adenocarcinoma.
    Am J Clin Oncol 2017 Jul 31. Epub 2017 Jul 31.
    Departments of *Radiation Oncology †Internal Medicine ‡Surgery, University of Texas Southwestern Medical Center Dallas, TX.
    Objectives: There is interest in improving the tumoricidal effects of preoperative radiotherapy for rectal carcinoma by studying new radiosensitizers. The safety and toxicity profile of these combination regimens needs rigorous clinical evaluation. The primary objective of this study was to evaluate the toxicity of combining bavituximab, an antibody that targets exposed phosphatidylserine, with capecitabine and radiation therapy. Read More

    Efficacy of Modified Dose-dense Paclitaxel in Recurrent Cervical Cancer.
    Am J Clin Oncol 2017 Jul 31. Epub 2017 Jul 31.
    *Department of Obstetrics and Gynecology, Division of Gynecologic Oncology †Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA.
    Objective: To examine survival outcomes of women with recurrent cervical cancer who received salvage chemotherapy with modified dose-dense paclitaxel (MDDP) monotherapy (paclitaxel 80 mg/m, administered on day 1, 8, and 15 without day 22).

    Materials And Methods: A retrospective study was conducted to evaluate cause-specific survival after the first recurrence (SAR) of women with recurrent cervical cancer diagnosed between 2006 and 2014. Pooled analyses were performed to examine SAR in women who received MDDP monotherapy (n=17) for any treatment line, compared with those who received salvage chemotherapy with paclitaxel-doublet (n=18) and nonpaclitaxel regimens (n=52). Read More

    Surgical Intervention in Gastric Carcinoid is Associated With Improved Survival in Local and Regional Disease.
    Am J Clin Oncol 2017 Jul 31. Epub 2017 Jul 31.
    Department of Surgery, City of Hope National Medical Center, Duarte, CA.
    Introduction: Gastric carcinoid is a rare entity with complex management options. This study aims to determine if surgical intervention in patients with local, regional, and metastatic gastric carcinoid is associated with prolonged survival.

    Materials And Methods: The California Cancer Registry merged with the California Office of Statewide Health Planning and Development was queried for patients with a diagnosis of gastric carcinoid (2000 to 2011). Read More

    Advanced Age is Not a Contraindication for Treatment With Curative Intent in Esophageal Cancer.
    Am J Clin Oncol 2017 Jul 31. Epub 2017 Jul 31.
    Departments of *Radiation Oncology †Surgical Oncology ‡Biometrics §Gastrointestinal Oncology ∥Pathology of The Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam, The Netherlands.
    Objectives: The objective of this study is to compare long-term outcomes between younger and older (70 y and above) esophageal cancer patients treated with curative intent.

    Materials And Methods: Overall survival (OS), disease-free survival (DFS), and locoregional recurrence-free interval were compared between older (70 y and above) and younger (below 70 y) esophageal cancer patients treated between 1998 and 2013. Treatment consisted of neoadjuvant chemoradiotherapy with surgery or definitive chemoradiotherapy: 36 to 50. Read More

    Hepatotoxicity After Immune Checkpoint Inhibitor Therapy in Melanoma: Natural Progression and Management.
    Am J Clin Oncol 2017 Jul 26. Epub 2017 Jul 26.
    *Department of Internal Medicine Divisions of †Medical Oncology ‡Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN.
    Objective: To report the clinical features, treatment, and outcomes of patients with immune checkpoint inhibitor-induced hepatotoxicity.

    Patients And Methods: In this retrospective observational study, we identified patients with metastatic malignant melanoma seen in consultation and/or treated between March 2011 and March 2016. Hepatotoxicity was assessed using the Common Terminology Criteria for Adverse Events, v4. Read More

    Capecitabine and Celecoxib as a Promising Therapy for Thymic Neoplasms.
    Am J Clin Oncol 2017 Jun 26. Epub 2017 Jun 26.
    *Department of Medicine §Committee on Clinical Pharmacology and Pharmacogenomics, University of Chicago, Chicago, IL †Florida Cancer Specialists and Research Institute, West Palm Beach, FL ‡Department of Medical Oncology and Therapeutics Research, City of Hope, and Beckman Research Institute, Duarte, CA.
    Objectives: For patients with unresectable or metastatic thymic epithelial neoplasms, few therapy options are available and outcomes are poor. This case series demonstrates that the combination of capecitabine and celecoxib may be a promising therapeutic option for these patients.

    Materials And Methods: The current report describes the outcomes of 5 patients with thymic neoplasms treated on a drug-drug interaction study of capecitabine and celecoxib in patients with advanced solid malignancies (NCT01705106) conducted at the University of Chicago, plus a sixth patient treated with the same regimen outside of the protocol. Read More

    Patterns of Adjuvant Therapy Utilization in Uterine Carcinosarcoma Stages I to III: A National Cancer Database Analysis.
    Am J Clin Oncol 2017 Jun 26. Epub 2017 Jun 26.
    *Department of Radiation Oncology †Division of Gynecologic Oncology, University of Colorado Denver, Aurora, CO.
    Objective: The objective of this study is to characterize patterns of utilization of adjuvant chemotherapy (CT) and radiotherapy (RT) in the posthysterectomy management of uterine carcinosarcoma (UCS) in the United States.

    Materials And Methods: We queried the National Cancer Database for women diagnosed with UCS between 2004 and 2012 and undergoing hysterectomy. Logistic regression was performed to identify sociodemographic, facility-specific, and treatment-related predictors of receiving multiagent chemotherapy, external beam radiotherapy (EBRT), or brachytherapy (BT). Read More

    Quantifying Decreased Radiation Exposure From Modern CT Scan Technology and Surveillance Programs of Germ Cell Tumors.
    Am J Clin Oncol 2017 Jun 26. Epub 2017 Jun 26.
    *Dana Farber Cancer Institute †Brigham and Women's Hospital ‡Harvard Medical School, Boston, MA.
    Introduction: Upgrading computerized tomography (CT) scanners to iterative reconstruction techniques (IRT) decreases radiation dose. This reduction, combined with changes in surveillance protocols in clinical stage I testicular cancer (CS1TC) measurably decrease the lifetime attributable risk (LAR) of dying of radiation-associated cancer.

    Materials And Methods: This IRB-approved study enrolled 24 CS1TC patients who had CT scans on the same Toshiba Aquilion 64 CT before and after IRT software installation. Read More

    Radiotherapy Alone or With Chemotherapy in the Management of Carcinoma of the Supraglottic Larynx: A 25-Year Community Hospital Experience.
    Am J Clin Oncol 2017 Jun 26. Epub 2017 Jun 26.
    *Phoebe Putney Memorial Hospital, Albany, GA †Department of Radiation Oncology, University of Florida College of Medicine, Gainesville, FL.
    Objectives: The purpose of this study was to retrospectively review outcomes for patients treated with definitive radiotherapy for carcinoma of the supraglottic larynx at a community hospital and to compare our results with the literature.

    Materials And Methods: Treatment records of 46 patients with localized carcinoma of the supraglottic larynx treated from January 1987 through January 2012 were reviewed. Overall, 18 (39%) presented with stage I or II disease, whereas 28 (61%) presented with stage III to IV. Read More

    Predictors of Local Recurrence in Patients With Myxofibrosarcoma.
    Am J Clin Oncol 2017 Jun 20. Epub 2017 Jun 20.
    *David Geffen School of Medicine Departments of †Radiation Oncology ‡Surgical Oncology §Hematology and Oncology ∥Pathology and Laboratory Medicine, University of California Los Angeles, Los Angeles, CA.
    Objectives: Myxofibrosarcoma (MFS) is reported to have a higher risk of local recurrence (LR) following definitive surgical excision relative to other soft tissue sarcomas. We reviewed our clinical experience treating MFS to investigate predictors of LR.

    Materials And Methods: We retrospectively reviewed treatment outcomes for MFS patients treated at our institution between 1999 and 2015. Read More

    Extraskeletal Osteosarcoma: Outcomes and the Role of Chemotherapy.
    Am J Clin Oncol 2017 Jun 15. Epub 2017 Jun 15.
    *Division of Medical Oncology Departments of †Laboratory Medicine and Pathology ‡Internal Medicine §Orthopedic Surgery ∥Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, MN.
    Objectives: Extraskeletal osteosarcoma (EO) is a malignant neoplasm that produces osteoid, bone, and chondroid material without direct attachment to bone or periosteum. Surgical resection is the mainstay of treatment; the role of chemotherapy is not well defined. Therefore, we evaluated the impact of chemotherapy in the survival of patients with EO. Read More

    Treatment and Outcomes of Primary Urethra Cancer.
    Am J Clin Oncol 2017 May 23. Epub 2017 May 23.
    Department of Radiation Oncology, University of Texas Health Science Center, San Antonio, TX.
    Background: Urethral cancer is a rare malignancy, representing <1% of all malignancies. Optimal management, due to its rarity, presents as a treatment dilemma for physicians. There is a lack of consensus regarding treatment as large randomized trials cannot be performed; thus, optimal management decisions rely on study of retrospective cases. Read More

    Impact of the Primary Information Source Used for Decision Making on Treatment Perceptions and Regret in Prostate Cancer.
    Am J Clin Oncol 2017 May 23. Epub 2017 May 23.
    Departments of *Radiation Oncology †Urology, University of California Los Angeles, Los Angeles, CA.
    Objective: To assess the impact of the primary source of information used by prostate cancer patients to select a radiation treatment on their overall treatment experience and on treatment regret.

    Methods: Patients with low to favorable intermediate-risk prostate cancer treated with stereotactic body radiation therapy, intensity-modulated radiation therapy, or high-dose rate brachytherapy were surveyed. The questionnaire explored the decision-making experience, treatment experience, and treatment regret. Read More

    Obesity is Independently Associated With Increased Risk of Hepatocellular Cancer-related Mortality: A Systematic Review and Meta-Analysis.
    Am J Clin Oncol 2017 May 23. Epub 2017 May 23.
    *Department of Internal Medicine ¶Division of Hematology Oncology, University of Texas Southwestern Medical Center §University of Texas Southwestern Medical Center Library, Dallas, TX †Division of Cardiology, Massachusetts General Hospital, Boston, MA ‡Department of Surgical Sciences, University of Minnesota, Minneapolis, MN ∥Division of Hematology/Oncology, Springfield Clinic, Springfield, IL #Division of Gastroenterology, University of California San Diego, La Jolla, CA.
    Objective: Excess body weight is associated with increased risk of developing hepatocellular cancer (HCC), but its effect on HCC-related mortality remains unclear. We performed a systematic review and meta-analysis to assess the association between premorbid obesity and HCC-related mortality.

    Materials And Methods: Through a systematic literature search-up to March 2016, we identified 9 observational studies (1,599,453 individuals, 5705 HCC-related deaths) reporting the association between premorbid body mass index (BMI), and HCC-related mortality. Read More

    Prevention of Trastuzumab and Anthracycline-induced Cardiotoxicity Using Angiotensin-converting Enzyme Inhibitors or β-blockers in Older Adults With Breast Cancer.
    Am J Clin Oncol 2017 May 23. Epub 2017 May 23.
    *Harrison School of Pharmacy †College of Sciences and Mathematics, Auburn University ‡East Alabama Medical Center §Department of Internal Medicine, Edward via College of Osteopathic Medicine, Auburn, AL.
    Purpose: Although clinical trials have provided some data on the benefit of angiotensin-converting enzyme inhibitors (ACEIs) or β-blockers (BBs) in patients with chemotherapy-induced cardiotoxicity, evidence of ACEIs/BBs on prevention of trastuzumab and/or anthracycline-induced cardiotoxicity outside trials is limited.

    Materials And Methods: A cohort study of 142,990 women (66 y and above) newly diagnosed with breast cancer from 2001 to 2009 was conducted using the Surveillance, Epidemiology, and End Results-Medicare-linked database. The ACEI/BB exposure was defined as filled prescription(s) before or after the initiation of trastuzumab/anthracyclines. Read More

    Assessment of the Albumin-Bilirubin (ALBI) Grade as a Prognostic Indicator for Hepatocellular Carcinoma Patients Treated With Radioembolization.
    Am J Clin Oncol 2017 Apr 17. Epub 2017 Apr 17.
    *Department of Radiation Oncology ¶Division of Surgery, Rutgers Cancer Institute of New Jersey ‡Department of Radiology, Rutgers Robert Wood Johnson University Hospital, New Brunswick §Department of Biostatistics, Rutgers School of Public Health, Piscataway, NJ †Department of Radiation Oncology, Washington University School of Medicine ∥Department of Radiology, Washington University, St Louis, MO #Department of Radiation Oncology, University of Colorado, Denver, CO.
    Objective: As the utility of Child-Pugh (C-P) class is limited by the subjectivity of ascites and encephalopathy, we evaluated a previously established objective method, the albumin-bilirubin (ALBI) grade, as a prognosticator for yttrium-90 radioembolization (RE) treatment for patients with hepatocellular carcinoma (HCC).

    Materials And Methods: A total of 117 patients who received RE for HCC from 2 academic centers were reviewed and stratified by ALBI grade, C-P class, and Barcelona Clinic Liver Cancer stage. The overall survival (OS) according to these 3 criteria was evaluated by Kaplan-Meier survival analysis. Read More

    Concurrent Chemoradiotherapy in the Adjuvant Treatment of High-risk Primary Salivary Gland Malignancies.
    Am J Clin Oncol 2017 Apr 7. Epub 2017 Apr 7.
    Departments of *Radiation Oncology, Cancer Institute †Medicine, Division of Medical Oncology ‡Otolaryngology, Head and Neck Surgery, University of Pittsburgh, Pittsburgh, PA.
    Objectives: Adjuvant radiation therapy (RT) is indicated for patients with salivary gland malignancies with risk factors for recurrence following resection. We analyzed patients treated with adjuvant RT with or without concurrent chemotherapy to determine the impact of prognostic and treatment factors.

    Materials And Methods: Retrospective analysis was performed of 128 patients treated with surgical resection followed by intensity-modulated radiotherapy. Read More

    Predictive Impact of Clinical Benefit in Chemotherapy-treated Advanced Pancreatic Cancer Patients in Northern Alberta.
    Am J Clin Oncol 2017 Mar 31. Epub 2017 Mar 31.
    *Department of Medical Oncology and Haematology, University of Manitoba, Winnipeg, MB ‡Covenant Health Palliative Institute †Department of Medical Oncology §Division of Palliative Care Medicine, University of Alberta, Edmonton, AB, Canada.
    Objectives: Patients with advanced pancreatic cancer (APC) have a poor prognosis and experience a large burden of disease-related symptoms. Despite advancements in the treatment of APC, survival is dismal and controlling disease-related symptoms and maintaining quality of life is paramount. We hypothesize that an improvement in disease-related symptoms, and therefore, a clinical benefit, while on chemotherapy is a predictive marker in APC. Read More

    Axillary Ultrasound Fine Needle Aspiration Biopsy: Is There a Role in the Post Z-0011 Era?
    Am J Clin Oncol 2017 Mar 23. Epub 2017 Mar 23.
    *St Peter's Health Partners, Albany, NY †Hartford Hospital, Hartford, CT ‡Breast Health Center, Women & Infants Hospital, Warren Alpert Medical School of Brown University, Providence, RI §Massachusetts General Hospital, Boston, MA.
    Objectives: Axillary ultrasound with fine needle aspiration (AXUSFNA) in early-stage breast cancer has required reappraisal. ACOSOG Z-0011 and after mapping of the axilla: radiotherapy or surgery have shown that women with limited nodal disease at sentinel lymph node biopsy got no survival advantage with completion axillary node dissection. We hypothesize that AXUSFNA may be sufficiently accurate for staging for some patients and sentinel lymph node biopsy need not be performed. Read More

    Clinical Use and Optimal Cutoff Value of Ca15-3 in Evaluation of Adnexal Mass: Retrospective Cohort Study and Review of the Literature.
    Am J Clin Oncol 2017 Mar 23. Epub 2017 Mar 23.
    *Department of Obstetrics and Gynecology †Carmel Medical Center, Genetics Institute ‡Department of Obstetrics and Gynecology, Bnai Zion Medical Center, Haifa, Israel.
    Objective: To estimate the diagnostic performance and reference values of serum cancer antigen (Ca)15-3 levels in the triage of adnexal masses.

    Materials And Methods: This retrospective cohort study was carried out in 481 patients referred to the Gynecology Department at Carmel Medical Center due to adnexal mass between years 2005 and 2012. All patients underwent surgery with histopathologically confirmed diagnosis and routine preoperative measurements of serum Ca125 and Ca15-3. Read More

    A Phase II Study of Ganetespib as Second-line or Third-line Therapy for Metastatic Pancreatic Cancer.
    Am J Clin Oncol 2017 Mar 15. Epub 2017 Mar 15.
    *Department of Medicine †Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center §Department of Cancer Biostatistics, Vanderbilt University Medical Center, Nashville ‡The Jones Clinic, Germantown, TN.
    Objectives: Heat shock protein 90 regulates multiple signaling proteins involved in key pathways of pancreatic cancer pathogenesis. Ganetespib binds to heat shock protein 90 and interferes with its binding to client proteins thus leading to inactivation and degradation of the signaling proteins that promote cancer progression. This phase II study was designed to evaluate the efficacy of ganetespib in patients with refractory metastatic pancreatic cancer (rMPC). Read More

    Influence of Extent of Lymph Node Evaluation on Survival for Pathologically Lymph Node Negative Non-Small Cell Lung Cancer.
    Am J Clin Oncol 2017 Mar 15. Epub 2017 Mar 15.
    *New York University School of Medicine †Icahn School of Medicine at Mount Sinai New York, NY ‡VA-NYHHS, Brooklyn Campus, Brooklyn, NY.
    Objectives: Despite previous retrospective reports that the number of lymph nodes resected at curative intent surgery for lung cancer correlates with overall survival (OS), no consensus exists regarding the minimal nor optimal number of lymph nodes to resect at curative lung cancer surgery.

    Methods: We studied subjects in the Surveillance Epidemiology and End Results Database (SEER) diagnosed with non-small cell lung cancer between 2000 and 2011 who underwent either lobectomy or pneumonectomy and had pathologic negative nodal evaluation. We excluded patients with sublobar resection and/or no lymph node evaluation. Read More

    Discord Among Radiation Oncologists and Urologists in the Postoperative Management of High-Risk Prostate Cancer.
    Am J Clin Oncol 2017 Mar 15. Epub 2017 Mar 15.
    Departments of *Radiation Oncology ‡Urology §Internal Medicine, Division of Hematology and Oncology, David Geffen School of Medicine, University of California, Los Angeles ∥Division of Hematology-Oncology, VA Greater Los Angeles Healthcare System, Los Angeles, CA †Sir Peter MacCallum Department of Oncology, the University of Melbourne, Vic., Australia.
    Objective: To query specialty-specific differences regarding postoperative radiotherapy (RT) for high-risk prostate cancer.

    Materials And Methods: Electronic mail survey of radiation oncologists (ROs) and urologists. We sought to maximize absolute response number to capture contemporary practice ethos. Read More

    Outcomes for Anaplastic Glioma Treated With Radiation Therapy With or Without Concurrent Temozolomide.
    Am J Clin Oncol 2017 Mar 15. Epub 2017 Mar 15.
    Departments of *Radiation Oncology †Pathology §Neurosurgery ∥Internal Medicine, Section on Hematology and Oncology ¶Neurology #Cancer Biology ‡Brain Tumor Center of Excellence, Wake Forest School of Medicine, Winston-Salem, NC.
    Objectives: Postoperative management of anaplastic glioma remains without a clear standard of care-in this study we report outcomes for patients treated with radiotherapy (RT) with and without temozolomide (TMZ).

    Materials And Methods: We identified 71 consecutive patients with World Health Organization grade III glioma treated with either RT alone or with concurrent TMZ (RT+TMZ), between 2000 and 2013. Tumor histology was anaplastic astrocytoma in 42 patients, anaplastic oligodendroglioma in 25 patients, and anaplastic oligoastrocytoma in 4 patients. Read More

    Phase II Study of Adjuvant Chemoradiotherapy Using Docetaxel/Cisplatin/5-Fluorouracil Before and After Intensity-modulated Radiotherapy With Concurrent Docetaxel in Patients With Completely (R0) Resected Gastric Carcinoma.
    Am J Clin Oncol 2017 Mar 3. Epub 2017 Mar 3.
    *Department of Radiation Oncology, Shanghai General Hospital, Shanghai Jiaotong University, Shanghai †Department of Radiation Oncology, Jiangsu Cancer Hospital ‡Department of Radiation Oncology, Nanjing BenQ Medical Center §Department of Radiation Oncology, Nanjing Jiangning Hospital, Nanjing Medical University, Nanjing, P.R. China.
    Objectives: The Intergroup 0116 study has demonstrated a significant survival benefit for completely resected (R0) gastric cancer patients treated with a fluorouracil/leucovorin chemoradiotherapy regimen. However, this regimen is also toxic and less effective in terms of distant disease control. Therefore, a more efficacious and safer regimen is urgently needed. Read More

    Appendix-derived Pseudomyxoma Peritonei (PMP): Molecular Profiling Toward Treatment of a Rare Malignancy.
    Am J Clin Oncol 2017 Mar 3. Epub 2017 Mar 3.
    *Drexel University College of Medicine, Philadelphia, PA †Carolinas HealthCare System, Charlotte, NC.
    Objectives: Pseudomyxoma peritonei (PMP) is a rare malignancy originating from the appendix, characterized by disseminated mucinous tumor implants on peritoneal surfaces. We examined the role of multiplatform molecular profiling to study biomarker-guided treatment strategies for this rare malignancy.

    Methods: A total of 54 patients with appendix-derived PMP were included in the study. Read More

    The Role of Definitive Radiotherapy in Craniopharyngioma: A SEER Analysis.
    Am J Clin Oncol 2017 Mar 3. Epub 2017 Mar 3.
    *Department of Radiation Oncology, University of Nebraska Medical Center †Department of Biostatistics, College of Public Health, University of Nebraska, Omaha, NE ‡Department of Radiation Oncology, Columbia University Medical Center, New York, NY §Department of Neurosurgery, Penn State Milton S. Hershey Medical Center, Hershey, PA.
    Objective: Assess patterns of care in the management of craniopharyngioma, especially with respect to the use of radiation therapy (RT) alone (which has been understudied to date) as compared with gross total resection (GTR) and subtotal resection (STR) with adjuvant RT.

    Materials And Methods: The epidemiology, treatment modalities, and outcomes of patients with craniopharyngioma were studied using the Surveillance Epidemiology and End Results (SEER) database from 2004 to 2012. Survival was compared between treatment groups using Kaplan-Meier analysis and log-rank tests. Read More

    The Role of Radiotherapy in Early-stage Primary Diffuse Large B-Cell Lymphoma of the Waldeyer Ring: A Retrospective Cohort Study.
    Am J Clin Oncol 2017 Mar 3. Epub 2017 Mar 3.
    Department of Clinical Oncology, Tuen Mun Hospital, Tuen Mun, Hong Kong, People's Republic of China.
    Objectives: The role of radiotherapy (RT) in improving survival of patients with diffuse large B-cell lymphoma (DLBCL) of the Waldeyer ring (WR) remains controversial. Therefore, this retrospective cohort study aimed to determine the role of RT in the treatment of DLBCL of the WR as well as the effects of associated covariates.

    Materials And Methods: Patients (n=35) with stage I to II DLBCL of the WR who underwent treatment at our center between 1994 and 2010 were retrospectively investigated. Read More

    ACR Appropriateness Criteria® Resectable Pancreatic Cancer.
    Am J Clin Oncol 2017 Apr;40(2):109-117
    *University of Texas Health Science Center at San Antonio, San Antonio ¶University of Texas MD Anderson Cancer Center, Houston, TX †Cancer Center of Santa Barbara, Santa Barbara §§Stanford Cancer Institute, Stanford ¶¶University of California Los Angeles, Los Angeles, CA ‡Cleveland Clinic, Cleveland, OH ***Stritch School of Medicine Loyola University Chicago, Maywood §Rush University Medical Center, Chicago, IL ∥Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, American Society of Clinical Oncology †††Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University ##Johns Hopkins University, Baltimore, MD, American College of Surgeons #Henry Ford Hospital, Detroit, MI **University of Colorado School of Medicine Anschutz Medical Campus, Aurora, CO ††Rutgers Cancer Institute of New Jersey, Robert Wood Johnson Medical School, Rutgers University, New Brunswick, NJ ‡‡University of Pennsylvania, The Chester County Hospital, West Chester, PA ∥∥Banner MD Anderson Cancer Center, Gilbert, AZ.
    Management of resectable pancreatic adenocarcinoma continues to present a challenge due to a paucity of high-quality randomized studies. Administration of adjuvant chemotherapy is widely accepted due to the high risk of systemic spread associated with pancreatic adenocarcinoma, but the role of radiation therapy is less clear. This paper reviews literature associated with resectable pancreatic cancer to include prognostic factors to aid in the selection of patients appropriate for adjuvant therapies. Read More

    Adjuvant External Radiation Impacts Outcome of Pelvis-limited Stage III Endometrial Carcinoma: A Multi-institutional Study.
    Am J Clin Oncol 2017 Feb 20. Epub 2017 Feb 20.
    *Department of Radiation Oncology Divisions of ‡Gynecologic Oncology ††Biostatistics, UT Southwestern Medical Center, Dallas, TX Departments of §Gynecologic Oncology **Radiation Oncology, Loyola University Chicago, Maywood, IL †Department of Radiation Oncology, Davis Comprehensive Cancer Center, University of California, Sacramento, CA ¶Henry Ford Hospital, Division of Radiation Oncology, Detroit, MI ∥Department Gynecological Oncology, UH Case Medical Center, Cleveland, OH.
    Background: Adjuvant therapy choice for women with FIGO stage III endometrial carcinoma (EC) is controversial. We investigate the comparative benefit of adjuvant chemotherapy (CT) alone, radiation therapy alone (RT) or in combination (chemotherapy and radiation therapy [CRT]) with respect to recurrence-free survival (RFS) and overall survival (OS) in women with pelvis-limited (PL) EC (stage IIIA, IIIB, and IIIC1).

    Materials And Methods: A multi-institutional database of 270 surgically staged women with PLEC was analyzed. Read More

    Adjuvant Radiotherapy Versus Wait-and-See Strategy for Pathologic T3 or Margin-Positive Prostate Cancer: A Meta-Analysis.
    Am J Clin Oncol 2017 Feb 20. Epub 2017 Feb 20.
    *Department of Radiation Oncology, Stritch School of Medicine †Research Methodology, School of Education, Loyola University-Chicago, Chicago, IL.
    Objective: To conduct a meta-analysis of the randomized controlled trials (RCTs) comparing adjuvant radiotherapy (ART) to wait-and-see (WS) strategy in pathologic T3 or margin-positive prostate cancer.

    Methods: A comprehensive EMBASE, MEDLINE, http://www.clinicaltrails. Read More

    Third-line Salvage Chemotherapy for Recurrent Carcinoma of the Cervix is Associated With Minimal Response Rate and High Toxicity.
    Am J Clin Oncol 2017 Feb 20. Epub 2017 Feb 20.
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Texas Southwestern Medical Center, Dallas, TX.
    Background: Metastatic and recurrent cervical cancer is rarely a curable disease. Systemic chemotherapy is typically recommended for treatment based on clinical trials in the first-line or second-line setting. Rare patients who progress through 2 salvage regimens will have the performance status, medical ability, and desire to continue cytotoxic therapy. Read More

    Challenges in Management of Squamous Cell Carcinoma of the Anus in New England and Across the United States: A Review of the National Cancer Data Base.
    Am J Clin Oncol 2017 Feb 6. Epub 2017 Feb 6.
    *Department of Surgery, Southcoast Health, New Bedford ‡Harvard University, Cambridge, MA †Alpert Medical School of Brown University, Providence, RI §Yale University, New Haven, CT.
    Background: Management of squamous cell carcinoma of the anus (SCCA) is becoming more relevant, as its incidence continues to increase. The purpose of this study was to evaluate regional and national data to assess trends in epidemiology, access to cancer center care, and overall management strategies in SCCA.

    Study Design: A review of available data from the American College of Surgeons Committee on Cancer National Cancer Data Base focused on incidence, sex, age, stage at diagnosis, distance traveled for care, and utilization of therapy as first course of treatment (FCT). Read More

    Tolerability and Long-term Outcomes of Dose-Painted Neoadjuvant Chemoradiation to Regions of Vessel Involvement in Borderline or Locally Advanced Pancreatic Cancer.
    Am J Clin Oncol 2017 Jan 27. Epub 2017 Jan 27.
    Departments of *Radiation Oncology †Medical Oncology ‡General Surgery, Massachusetts General Hospital, Boston, MA.
    Purpose: We reviewed our experience involving patients with borderline resectable or locally advanced pancreatic cancer, treated with the dose-painted (DP) boost technique to regions of vessel involvement which preclude upfront surgical resection. We evaluated patient outcomes with respect to tolerability and treatment outcomes.

    Materials And Methods: We retrospectively reviewed 99 patients with borderline resectable (n=25) or locally advanced pancreatic cancer (n=74) treated with DP-neoadjuvant chemoradiation from 2010 to 2015. Read More

    Chemoradiation Versus Chemotherapy in Uterine Carcinosarcoma: Patterns of Care and Impact on Overall Survival.
    Am J Clin Oncol 2017 Jan 24. Epub 2017 Jan 24.
    *David Geffen School of Medicine at UCLA, Los Angeles, CA †Department of Radiation Oncology, Huntsman Cancer Hospital ‡Clinical Trials Office, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT.
    Objectives: Uterine carcinosarcoma (UCS) is a rare and aggressive cancer with poor survival. Our purpose was to evaluate the patterns-of-care and overall survival (OS) benefit of adjuvant chemoradiation (aCRT) compared with adjuvant chemotherapy (aCT) among UCS patients.

    Methods: A query was made in the National Cancer Database to identify patients with UCS diagnosed between 2004 and 2012. Read More

    Suboptimal Compliance With National Comprehensive Cancer Network Melanoma Guidelines: Who Is at Risk?
    Am J Clin Oncol 2017 Jan 24. Epub 2017 Jan 24.
    *Department of Surgery, Rhode Island Hospital †Department of Surgery, Warren Alpert Medical School of Brown University, Providence, RI.
    Background: National Comprehensive Cancer Network (NCCN) melanoma treatment guidelines are based on best available literature. We evaluated NCCN excision margin and sentinel lymph node biopsy (SLNB) guideline adherence to identify patient populations at risk for suboptimal care.

    Methods: Retrospective review of prospectively maintained database of all patients who underwent operation for invasive melanoma from January 2005 to 2015. Read More

    Response to Comments by Drs Hamaoka and Beyea on "The Birth of the Illegitimate Linear No-Threshold Model: An Invalid Paradigm for Estimating Risk Following Low-dose Radiation Exposure".
    Am J Clin Oncol 2017 Feb;40(1):106-107
    *Nuclear Physics Enterprises, Marlton, NJ †US FDA (Retired), Green Valley, AZ ‡NAC International, Alpharetta, GA §Department of Radiation Oncology, Stritch School of Medicine Loyola University-Chicago, Maywood, IL.

    1 OF 90